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Abstract During the last years, genome wide association
studies have discovered common germline genetic variants
associated with specific glioma subtypes. We aimed to
study the association between these germline risk variants
and tumor phenotypes, including copy number aberrations
and protein expression. A total of 91 glioma patients were
included. Thirteen well known genetic risk variants in
TERT, EGFR, CCDC26, CDKN2A, CDKN2B, PHLDB1,
TP53, and RTEL1 were selected for investigation of pos-
sible correlations with the glioma somatic markers: EGFR
amplification, 1p/19q codeletion and protein expression of
p53, Ki-67, and mutated IDH1. The CDKN2A/B risk
variant, rs4977756, and the CDKN2B risk variant,
rs1412829 were inversely associated (p = 0.049 and
p = 0.002, respectively) with absence of a mutated IDH1,
i.e., the majority of patients homozygous for the risk allele
showed no or low expression of mutated IDH1. The RTEL1
risk variant, rs6010620 was associated (p = 0.013) with
not having 1p/19q codeletion, i.e., the majority of patients
homozygous for the risk allele did not show 1p/19q
codeletion. In addition, the EGFR risk variant rs17172430
and the CDKN2B risk variant rs1412829, both showed a
trend for association (p = 0.055 and p = 0.051, respec-
tively) with increased EGFR copy number, i.e., the
majority of patients homozygote for the risk alleles showed
chromosomal gain or amplification of EGFR. Our findings
indicate that CDKN2A/B risk genotypes are associated with
primary glioblastoma without IDH mutation, and that there
is an inverse association between RTEL1 risk genotypes
and 1p/19q codeletion, suggesting that these genetic vari-
ants have a molecular impact on the genesis of high graded
brain tumors. Further experimental studies are needed to
delineate the functional mechanism of the association
between genotype and somatic genetic aberrations.
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Introduction
Glioma includes several subtypes. Traditionally, they have
been classified solely on histopathological features, though
classification is currently changing towards accounting for
molecular markers as well [1]. Previous studies have indi-
cated that subtypes of glioma display separate molecular and
genetic profiles resulting from their separate etiologic
pathways. The somatic mutations and aberrations are
sometimes correlated [2], such as the link between IDH1
mutation and 1p/19q codeletion in low grade glioma [3–5].
Some of these markers, like IDH1 mutation and MGMT
methylation, have diagnostic value and are useful prognostic
and predictive factors relating to patient survival and
response to treatment [6–10]. 1p/19q codeletion is thought to
be a distinguishing feature for oligodendroglioma and TP53
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mutations for astrocytoma, and even though they are not
mutually exclusive, they are a clear support in the diagnostic
classification [11]. IDH1 mutations are known as an
important diagnostic marker, especially for low graded
tumors and secondary glioblastoma [12, 13]. In combination
with loss of nuclear ATRX expression, IDH1, 1p/19q and
TERT promoter mutations define the most frequent type of
infiltrative astrocytoma [14, 15], while mutations in the
EGFR gene (seen in 35 % of all cases of glioblastoma) are
associated with primary glioblastoma [16]. In several of
these genes that typically harbor somatic mutations in
glioma, genome wide association studies (GWAS) have
discovered common germline variants that are associated
with risk of developing glioma, including variants in EGFR,
CDKN2A, TERT, and TP53 [17–22]. Furthermore, germline
variants at 8q24.21 are known to be associated with oligo-
dendroglial tumors and astrocytoma with mutated IDH1 or
IDH2 [23]. Several single nucleotide polymorphisms (SNPs)
have also been shown to associate with tumor grade. Vari-
ants in CDKN2B and RTEL1 are strongly associated with
high-grade glioma while variants in CCDC26 and PHLDB1
are associated with low-grade glioma [18, 24].
To investigate whether germline genetic risk variants are
linked to specific molecular characteristics of the tumor,
we selected 13 glioma risk variants established in the
previous studies, mainly GWAS (Supplementary Table 1),
and studied their correlation with the glioma somatic
biomarkers: EGFR alteration, 1p/19q codeletion, IDH1
mutation, p53 and Ki67 protein expression. We used
immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH) analyses to assess the biomarkers. In
addition, FISH results were compared with the results from
one of our previous studies, where somatic copy number
data were calculated from SNP array [25] profiles, to
explore if the different methods can detect similar genetic
aberrations.
Materials and methods
Study population and tumor specimens
Paraffin-embedded glioma tissues were available from 91
patients for the present study, and the sample set and its
characteristics are listed in Table 1. Histologically, 33 of
the tumors were grade II-III glioma and 58 were
glioblastoma (Table 1). The patients in the present study
overlap with the ones included in a paper by Wibom et al.
[25], where the ASCAT algorithm [26] was employed to
calculate somatic genome-wide allele-specific copy num-
ber profiles (i.e., ASCAT profiles). The overlap is consti-
tuted by 59 patients that were included in both studies
(Table 1; Supplementary Table 2). Informed consent was
obtained from all individual participants included in the
study. The ethical board approval was obtained for all
experiments, in accordance with the Umea˚ University
guidelines.
Immunohistochemistry (IHC)
A neuropathologist identified histologically representative
tumor regions that were stained by hematoxylin and eosin.
Tissue sections were cut at 4 lm and the IHC was per-
formed using the Ventana Benchmark system (Ventana
Medical System, Tucson, AZ, USA). As a pre-treatment
step, tissues were subjected to heat-induced epitope
retrieval with the Cell Conditioning 2 solution (Ventana,
Tucson, AZ, USA), 24 min for Ki-67 (30-9) (Ventana,
Tucson, AZ, USA), 32 min for p53 (DO-7) (Ventana,
Tucson, AZ, USA) and IDH1 (R132H) (Dianova, Ham-
burg, Germany). The antibody concentrations were 2 lg/
ml for Ki-67, 184 lg/ml for p53, and 4 lg/ml for IDH1.
Two independent observers evaluated the stained slides.
Proliferation index was evaluated using Ki-67 antibody
staining and calculated by determining the percentage of
immunopositive nuclei. A total of 100-500 nuclei were
counted. The tumors were divided into two groups, less
aggressive (\15 %) and more aggressive C15 %). The
consensus for p53 was scored in four different categories:
no immunoreactivity (0 %), faint (B50 %), moderate
(50–75 %), and strong (C75 %) immunoreactivity.
IDH1 was scored in two categories: (0–10 %) for nega-
tive immunoreactivity, and (C10 %) for positive
immunoreactivity.
Fluorescence in situ hybridization (FISH)
Tissue sections for 1p, 19q, and EGFR FISH staining were
cut at 4 lm. The slides were deparaffinized, dehydrated,
and placed in pretreatment solution (Vysis, Illinois, USA)
followed by rinse in purified H2O and 2 9 SSC. The slides
were then treated for 45 min in 50 ml of solution (NaCl pH
2.0) containing 25 mg protease (Vysis, Illinois, USA), and
rinsed in H2O and 2 9 SSC. Locus-specific probes for
EGFR (7p12), 1p36/1q13 and 19p13/19q13 were used as
recommended by the manufacturer (Vysis, Illinois, USA).
In short, probes were applied and a coverslip was placed
over the target area, followed by sealing with rubber
cement to prevent evaporation of the probe. Simultaneous
denaturation of the probe and target was carried out on the
THERMOBrite (Abbott Molecular, Illinois, USA) at 74 C
for 6 min. Hybridization was performed by placing the
slides in a humidified chamber at 37 C for overnight
incubation. After hybridization, slides were treated in a
post-hybridization wash of 2 9 SSC solution containing
0.3 % NP40 at 73 C and nuclei were counterstained by
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DAPI (Sigma-Aldrich, USA) nuclear counterstain. Anti-
fade (CitiFluor, London, UK) was applied and the sections
were viewed using a Zeiss Axio Imager Z1fluorescent
microscope with a dual green/orange filter (Vysis, Illinois,
USA). Three observers evaluated the slides and the eval-
uation was based on 100 intact non-overlapping nuclei that
were counted for both the green and orange signals. The
ratio of EGFR was calculated using the criteria developed
in previous studies [27–29]. A ratio between the locus
specific probe (EGFR) and the control probe CEP7 (EGFR/
CEP7) was calculated where ratios equal to 1 was con-
sidered as normal, while more than 10 % cells with a ratio
between 1 and 2 was considered as chromosomal gain and
more than 10 % cells with a ratio greater than 2 was
considered as amplification. The ratio between the locus
specific probe and control probe for both 1p (1p36/1q25)
and 19q (19q13/19p13) was calculated using the criteria
used in the clinical routine practice [30], 1p36/1q25
ratios\ 0.88 and 19q13/19p13 ratios\ 0.74 in more than
12 % of the cells were considered as deleted.
SNP array
Data was taken from our previous study [25] where DNA
was extracted from glioma tissue using QIAmp Mini Kit
(QIAGEN GmbH, Hilden, Germany) and genotyped using
Illumina HumanOmni1-Quad BeadChips. The ASCAT
algorithm [26] (version 2.0) was used to calculate somatic
whole-genome allele-specific copy number profiles
(ASCAT-profiles), as well as estimates of tumor cell content
and tumor cell ploidy. For comparison between FISH and
ASCAT, we extracted the median total copy number from
the ASCAT profiles for the genomic regions corresponding
to the FISH probes. These copy number data were subse-
quently used to mimic the sample classification based on
FISH data, by calculating the same ratios and using the same
cutoff values that had been used for classification by FISH.
More details about the SNPs can be found in supplementary
Table 1 and samples included in analyses with both FISH
and ASCAT are shown in Table 1.
Statistical analyses
The associations between the biomarkers and genetic risk
variants as well as comparisons of different methods were
evaluated using the v2 test or the Fisher’s exact test. The
significance level was set at p\0.05. Six genetic variants
(rs2252586, rs17172430, rs11979158, rs4295627, rs5570
5857, and rs78378222) were not genotyped by the SNP array.
Therefore, these variants were imputed using the software
IMPUTE2 with data from the 1000 Genomes Project as the
reference population. One SNP, rs55705857 was excluded
from further analysis since it could not be imputed with high
certainty (imputation score\0.80) (Supplementary Table 1).
Results
Eighty glioma patients were successfully analyzed for
EGFR copy number variation and 1p/19q codeletion,
however two samples were excluded since the ratio was
below 1 and there were too few patients to make a separate
group for these two samples. EGFR amplification was
observed in 24 of 78 (30.8 %) glioma tumors and in 18 of
47 (38.3 %) glioblastoma tumors. 1p/19q codeletion was
observed in 14 of 78 (17.9 %) glioma tumors and 8 of 50
Table 1 Summary of patient characteristics
Total number of patients included in the study 91 Total number of patients included in the study, ASCAT 59
Median age (years) 58 Median age (years) 58
Age range (years) 15–80 Age range (years) 15–80
No. (%) No. (%)
Male 53 (58.2) Male 35 (59.3)
Female 38 (41.8) Female 24 (40.7)
Histological subtypes Histological subtypes
Pleomorphic xanthoastrocytoma grade II 1 Pleomorphic xanthoastrocytoma grade II 0
Astrocytoma grade II 2 Astrocytoma grade II 0
Astrocytoma grade III 12 Astrocytoma grade III 9
Oligodendroglioma grade II 9 Oligodendroglioma grade II 6
Oligodendroglioma grade III 7 Oligodendroglioma grade III 4
Oligoastrocytoma grade II 1 Oligoastrocytoma grade II 1
Ganglioglioma 1 Ganglioglioma 1
Glioblastoma 58 Glioblastoma 38
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(16.0 %) glioblastoma tumors. Due to lack of patient
material and failed analyses different numbers of
glioblastoma tumors are analyzed for EGFR amplification
and 1p/19q codeletion (Table 2).
The blood samples corresponding to the tumor samples
were analyzed with the SNP array. Four genetic risk vari-
ants showed association with the investigated glioma
biomarkers (Table 3). The CDKN2A/B risk variant
(rs4977756) and the CDKN2B risk variant (rs1412829)
were both inversely associated with expression of mutated
IDH1 (p = 0.049 and p = 0.002, respectively) since for
both these variants, the majority of patients homozygous
for the risk allele (G) showed no or low (0–10 %
immunoreactivity) expression of mutated IDH1. The
CDKN2B risk variant, rs1412829 and the CDKN2A/B risk
variant, rs4977756 are both located on chromosome 9p21
within the same gene cluster as the non-coding RNA
CDKN2B-AS1 (also known as ANRIL), and these risk
variants are largely dependent of each other in terms of
linkage disequilibrium (LD) since they are both located
within the same haplotype block (r2 = 0.741; D0 = 0.888).
The RTEL1 risk variant (rs6010620) was inversely asso-
ciated with 1p/19q codeletion (p = 0.013) since the
majority of patients homozygous for the risk allele (G)
showed no 1p/19q codeletion. In addition, we observed a
trend of higher frequency of EGFR amplified tumors in
patients homozygous for the EGFR risk variant
(rs17172430) and the CDKN2B risk variant (rs1412829).
This finding was however not statistically significant. None
of the other evaluated risk variants showed any significant
associations with the investigated glioma biomarkers.
To compare the copy number profiles achieved by
applying ASCAT to SNP array data with results from the
FISH analysis, we focused on 1p/19q codeletion and EGFR
amplification, because these features have clinical impli-
cations. For 1p/19q codeletion, there were 55 patients with
data from both methods available, and 59 patients with data
from both methods were available for EGFR amplification.
The comparison yielded entirely disparate results with
regards to 1p/19q codeletion, where FISH detected 14
samples displaying this aberration whereas none was
detected based on SNP array data (Supplementary
Table 3). The similarity in results from the two techniques
was greater with regards to EGFR amplification. Using
FISH, we detected 24 samples with EGFR amplification, of
these 23 had ASCAT profiles available and 17 of them
displayed EGFR amplification also by the SNP array
approach (Table 4). In addition, 3 samples displayed
chromosomal gain in EGFR as analyzed by FISH, of these
2 had ASCAT profiles available but none of them dis-
played chromosomal gain in EGFR also by the SNP array
approach (Table 4).
Based on proliferation index, 46 of 91 glioma tumors
were considered less aggressive and 45 of 91 were more
aggressive. Expression of mutated IDH1 was found in 15
Table 2 Protein expression by means of IHC staining and copy
number variation by means of FISH analysis for the glioma
biomarkers
Glioma biomarkers Number (%)
Ki67a
\15 % 46/91 (50.5)

























No codeletion 64/78 (82.1)
1p/19q, glioblastomab
Codeletion 8/50 (16.0)
No codeletion 42/50 (84.0)
Ki67 proliferation index was scored for percentage of positive nuclei
in a cell population and dived into less aggressive (\15 %) and more
aggressive ([15 %) groups. IDH1 protein expression was scored as
(0–10 %) for negative, and ([10 %) for positive immunoreactivity
and p53 protein expression was scored as (0 %) for negative,
(25–50 %) for faint, (50–75 %) for moderate (since there were too
few cases in this group, faint and moderate expression was merged as
one group for statistical analysis), and ([70 %) for strong
immunoreactivity. Due to lack of patient material and failed analyses
different numbers of samples are analyzed for the different
biomarkers
a Immunohistochemistry (IHC) staining
b Fluoroscence in situ hybridization (FISH) analysis
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of 90 glioma tumors, whereas 4 of 57 cases in the
glioblastoma subgroup were positive for mutated IDH1.
Almost all glioma patients, 85 of 89, showed p53
expression. In the glioblastoma subgroup, 38 of 56 showed
faint to moderate protein expression while 17 patients
demonstrated strong p53 protein expression (Fig. 1). Due
to lack of patient material and failed analyses different
numbers of samples are analyzed for the different
biomarkers.
Discussion
There are specific molecular markers in glioma character-
ization used to define the histological subtypes and grades
of malignancy, as well as markers of diagnostic and
prognostic value, and markers that may be used to predict
response to treatment. Exploring an association between
germline genetic variation and molecular alterations could
be a key for definition of unique molecular based subtypes
of glioma.
Previous studies have observed that some genetic vari-
ants are associated with tumor grade, like risk variants in
the CDKN2B, RTEL1, and TERT regions [18, 31], which
show association with high grade glioma, while risk vari-
ants in the CCDC26 and PHLDB1 regions are associated
with low grade glioma involving IDH mutation, and 1p/19q
codeletion [17, 31]. Although, association with tumor
grade was not analyzed in our study due to the small
number of low grade glioma, we found two risk variants in
the CDKN2A and CDKN2B regions associated with
mutated IDH1 (Table 3). The risk variant near CDKN2B
(rs1412829) is the same risk variant associated with tumor
grade in the study by Wrensch et al. [18]. We found
expression of mutated IDH1 in few glioblastoma cases,
which is in concordance with previous studies [4]. These
findings might have clinical implications as a potential
predictive marker, since recently updated data from the
RTOG 9402 trial showed that IDH mutations predict the
benefit of adjuvant chemotherapy in grade III glioma [32].
Other studies have shown that oligodendroglial tumors and
glioma with mutated IDH1 are strongly associated with the
chromosome 8q24.21 risk variant (rs55705857) [23].
Conversely, and probably due to low statistical power in
our study, we do not see any strong association between
IDH1 mutations and the chromosome 8q24.21 risk variant.
One risk variant in RTEL1 (rs6010620) that previously has
shown association with 1p/19q codeletion [31], was sig-
nificantly associated with 1p/19q codeletion also in our
study. It has earlier been shown that genetic variants within
or near the RTEL1 (20q13) regions are strongly associated
with glioblastoma [33]. RTEL1 has been hypothesized to be
involved in the resolution of D loops that occur during
homologous recombination, and is together with TERT
supposed to play a role in regulating telomere length [34,
35]. We found an inverse association between 1p/19q
Table 3 Association between genetic risk variants and molecular
alteration
Mutated IDH1, IHC Negative (%) Positive (%) p value
CDKN2A/2B_rs4977756
AA 14 (66.7) 7 (33.3) 0.049
AG 34 (91.9) 3 (8.1)
GG 20 (83.3) 4 (16.7)
AG ? GG 54 (88.5) 7 (11.5) 0.022
Mutated IDH1, IHC Negative (%) Positive (%) p value
CDKN2B_rs1412829
AA 10 (55.6) 8 (44.4) 0.002
AG 38 (92.7) 3 (7.3)
GG 20 (87.0) 3 (13.0)
AG ? GG 58 (90.6) 6 (9.4) 0.0005
1p/19q loss, FISH No codeletion (%) Codeletion (%) p value
RTEL1_6010620
GG 38 (84.4) 7 (15.6) 0.013
AG 17 (85.0) 3 (15.0)
AA 1 (25.0) 3 (75.0)











AA 1 (7.1) 11 (78.6) 2 (14.3) 0.051
AG 9 (25.0) 17 (47.2) 10 (27.8)
GG 2 (9.1) 9 (40.9) 11 (50.0)











GG 11 (21.1) 21 (40.4) 20 (38.5) 0.055
AG 0 (0.0) 11 (78.6) 3 (21.4)
AA 0 (0.0) 2 (100.0) 0 (0.0)
AG ? AA 0 (0.0) 13 (81.2) 3 (8.8) 0.017
Samples were classified as positive or negative for expression of
mutated IDH1 based on the percentage of positive nuclei; B10 % for
negative and[10 % for positive. 1p36/1q25 ratios\0.88 and 19q13/
19p13 ratios\0.74 in more than 12 % of the cells were considered as
codeleted. EGFR copy number aberrations were classified based on
the EGFR/CEP 7 ratio; ratio = 1 was classified as normal, ratio
between 1 and 2 in[10 % of the cells was classified as gain, ratio[2
in[10 % of the cells was classified as amplified. The total number of
samples listed for each association may differ, due to missing geno-
type data
IHC Immunohistochemistry, FISH fluorescence in situ hybridization
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codeletion and the risk variant in RTEL1 (rs6010620) but
not the risk variant in TERT (rs2736100). Although the
number of patients homozygous for the non-risk genotype
in this comparison was only 4, our results are in line with
previous studies, and suggest that germline glioma risk
variants might be involved in the development and pro-
gression of high grade glioma. Nevertheless, since the
majority of the genetic variants analyzed in this study are
located in introns or intergenic regions, and do not result in
amino acid changes in transcribed proteins, the mechanism
of action behind these associations need to be further
elucidated.
We have previously shown that two risk variants
(rs17172430 and rs11979158) in EGFR are associated with
homozygous deletion at the CDKN2A/B locus, and that one
of the risk variants (rs17172430) in EGFR also shows
association with allele specific loss of heterozygosity at the
EGFR locus [25]. In this study, both the EGFR risk variant
(rs17172430) and the CDKN2B risk variant (rs1412829)
showed a trend for an association with chromosomal gain
and amplification in EGFR. Similar trends were observed
in the same sample set based on ASCAT copy number
profiles, but they did not validate when tested on a TCGA
data set in our previous study [25]. The association with
chromosomal gain might indicate that these genotypes are
associated with increased genetic instability where the
tumor is more prone to have genetic aberrations with loss
of one allele and copy number increase of the remaining
allele. The genetic variants in EGFR that have been asso-
ciated with glioma risk are not closely linked in the
Table 4 Patients displaying chromosomal gain and amplification in EGFR as observed by FISH analysis and results from corresponding
analyses on ASCAT profiles


















1 Glioblastoma 90 Yes X
2 Glioblastoma 80 Yes X
3 Glioblastoma 100 Yes X
4 Glioblastoma 100 Yes X
5 Oligodendroglioma grade III 100 Yes X
6 Glioblastoma 85 Yes X
7 Glioblastoma 100 Yes X
8 Astrocytoma grade III 100 No
9 Oligodendroglioma grade III 95 No
10 Glioblastoma 85 Yes X
11 Oligodendroglioma grade II 65 Yes X
12 Glioblastoma 100 Yes X
13 Glioblastoma 91 Yes X
14 Astrocytoma grade III 100 Yes X
15 Oligodendroglioma grade III 55 No
16 Glioblastoma 97 No
18 Astrocytoma grade III 86 Yes X
19 Glioblastoma 35 Yes X
20 Glioblastoma 30 Yes X
21 Glioblastoma 69 Yes X
22 Glioblastoma 40 Yes X
23 Glioblastoma 100 Yes X
24 Glioblastoma 100 Yes X
25 Glioblastoma 90 Yes X
26 Glioblastoma 100 Yes X
27 Glioblastoma 100 Yes X
28 Glioblastoma 100 Yes X
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genome, and therefore these genotypes could give disparate
result. In this study, the sample number is relatively small
and thus suffering from limited statistical power to detect
associations, particularly affecting low-frequency variants
and variants with small effect size. The genotype-pheno-
type associations are not significant following adjustment
to the family-wise error rate (Bonferroni correction).
However, this procedure to adjust for multiple testing
might be too stringent given that some investigated vari-
ables in this study are not independent. Larger glioma
studies with dense tagging of the EGFR gene are required
to elucidate the number of true associated genetic variants.
In addition, we have compared the present study with a
previous study, where ASCAT profiles were calculated on
a set of samples that overlapped with the samples included
in this study. We observed that the different methodologies
identifies dissimilar types of genetic aberrations. The SNP
array approach cover the whole genome but might be
considered less sensitive than FISH to detect aberrations in
tumor subclones. For 1p/19q codeletion, the aberrations
that the FISH analysis detected was not identified by the
ASCAT analysis (data not shown), while for EGFR, results
from the two methods showed a better correlation
(Table 4). Both methods compared in this study have
advantages and disadvantages. Establishment of a good
threshold level for positive results is important for avoiding
over interpretation of small cell populations when using
FISH analysis and SNP array. However, the threshold for
1p/19q codeletion is well established in the clinic [30] and
the threshold of EGFR amplification is well studied [27–
29]. The FISH analysis technique uses fluorescently
labeled DNA probes to detect chromosomal abnormalities.
Applying ASCAT to SNP array data allow us to estimate
both tumor cell content and tumor cell ploidy, which
cannot be detected by FISH analysis. A uniparental dis-
omy, when cancer cells have lost one chromosome in the
presence of duplication of the other chromosomal allele,
cannot be detected by FISH analysis, while this can be
detected by ASCAT. FISH analysis with locus-specific
probe does not allow testing for multiple chromosomal loci
Fig. 1 Immunohistochemical
staining for p53 and mutated
IDH1. Expression of p53 was
scored in four different
categories: a negative, b faint
expression, c moderate
expression, d strong expression.
Expression of mutated IDH1
was scored for either e negative,
or f positive
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which can be detected by SNP arrays. On the other hand,
the ASCAT algorithm assumes that the tumor sample is
from the same clone and will ignore the heterogeneity of
the tumor, which is a well-known aspect of glioma and this
could be an explanation why ASCAT fails to detect 1p/19q
codeletion.
In conclusion, even though the results need to be taken
with caution since this study represents a small sample
size, we found inverse associations between genetic risk
variants in CDKN2A/2B, RTEL1 IDH1 mutation and 1p/
19q codeletion, in line with previous studies. Whereas the
results revealing that risk variants in EGFR and CDKN2B
both showed a trend for association with EGFR copy
number variation are new findings. The idea that the
genetic variants could be used as a complementary diag-
nostic approach for tumors difficult to assess for conclusive
biopsies is an interesting diagnostic concept in glioma,
where there seem to be a limited number of genetic pre-
disposing loci and robust biomarkers that might be added
to diagnostics.
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